10-Q · May 8, 2026
Creative Medical Technology Holdings, Inc. reported no revenue for Q1 2026, a significant drop from $3,000 in Q1 2025, resulting in a gross profit decline to $0. Operating loss narrowed slightly to $1,459,153 from…
Earnings analysis · 10-Q
CELZ earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or risk-factor section, so revenue, margins, EPS, liquidity, working-capital trends, free cash flow, and segment…
Read full summary
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or risk-factor section, so revenue, margins, EPS, liquidity, working-capital trends, free cash flow, and segment performance cannot be assessed from the available text. No quantitative guidance is provided. Management reported effective disclosure controls in Item 4, while Item 1 retains a general warning regarding potential litigation.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls assessed as effective
In Item 4, management concluded that disclosure controls and procedures were effective as of the end of the reporting period. The filing also states there were no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, those controls.
What to watch
-
Unquantified litigation exposure
Item 1 states that the company may become involved in various lawsuits and legal proceedings and warns that an adverse result could harm the business. The filing provides no quantified litigation exposure.
Management's outlook
No quantitative outlook or forward guidance is provided in the supplied 10-Q extract. The extract contains no revenue, EPS, liquidity, or capital-spending outlook.
Earlier filings 4
10-K · April 24, 2026
The 2025 Form 10-K/A shows Creative Medical is continuing to invest in its cell-therapy platform (notably a $5,000,000 research-tools acquisition recorded as R&D) while retaining a small public footprint (3,696,668…
10-K · March 20, 2026
Creative Medical (CELZ) is a clinical-stage regenerative-therapy company with multiple cell therapy platforms (ImmCelz, AlloStem, iPScelz) and limited commercial products (CaverStem/FemCelz). The 2025 10-K shows…
10-Q · November 7, 2025
Creative Medical reported Q3 (three months ended September 30, 2025) results showing zero revenue and a GAAP net loss of $1,235,934, or $(0.48) per share. Cash declined modestly to $5.38M at September 30, 2025, and the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.